Combination Treatment with PPARγ Ligand and Its Specific Inhibitor GW9662 Downregulates BIS and 14-3-3 Gamma, Inhibiting Stem-Like Properties in Glioblastoma Cells

Figure 2

Combined treatment with PPARγ ligand and GW9662 downregulated survival-related signaling molecules and stemness-related marker protein SOX2. After treatment with PPARγ ligands (CG, 10 μM ciglitazone; RS, 100 μM rosiglitazone) with or without 20 μM GW9662 (GW) for 48 h, monolayer cells or spheres of A172 (a) or U87 (b) were analyzed via western blotting with specific antibodies and the intensity of each protein per β-actin was measured using ImageJ software (right panels) as described in Materials and Methods. and versus control group without treatment. and , versus only GW treated group.

(a)

(b)